论文部分内容阅读
在罗马召开的欧洲抗风湿病联盟(EULAR)2010年年会上发布的一项Ⅱ期临床研究报告显示,诺华公司开发并上市的注射用IL-1阻滞剂canaki-numab(Ilaris,即人抗IL-1β单克隆抗体)较抗炎药秋水仙碱更能显著地降低痛风患者急性发作率。这项为期24周的双盲Ⅱ期临床研究涉及432名年龄20~70
A Phase II clinical study released at the 2010 Annual Meeting of the European Union of Anti-Rheumatism (EULAR) in Rome showed that Novartis’s IL-1 blocker for injection, canaki-numab (Ilaris, Anti-IL-1β monoclonal antibody) significantly reduced the incidence of acute gout in patients with gout compared with the anti-inflammatory drug colchicine. The 24-week double-blind Phase II clinical trial involved 432 patients aged 20-70